NCIt definition : A bispecific antibody targeting both the human negative immunoregulatory checkpoint
receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human
programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating
and antineoplastic activities. Upon administration, reozalimab simultaneously targets
and binds to PD-1, which is expressed on a variety of leukocyte subsets including
activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1 expressed on
tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1
and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation.
This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances
cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor
growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival
of CD8-positive T-cells, suppresses the immune system and results in immune evasion.;
Semantic type(s)